Eindhoven-based medtech startup developing in-vitro diagnostic (IVD) solutions for ultra-rapid, direct-from-sample antimicrobial susceptibility testing (AST) that delivers results within an hour using proprietary chemistry.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €15 M | Jan, 2026 | seed |
Industries
Frequently Asked Questions
Where is ShanX Medtech located?
ShanX Medtech is located in Eindhoven, Netherlands.
What industries does ShanX Medtech operate in?
ShanX Medtech operates in the following industries: medtech, in-vitro diagnostics, healthcare, biotech, diagnostics.
When was ShanX Medtech founded?
ShanX Medtech was founded on 2026-01-08.
How much total funding has ShanX Medtech raised?
ShanX Medtech has raised a total of $15,000,000.
Who are the investors in ShanX Medtech?
The investors in ShanX Medtech are: NextGen Ventures, CbusineZ, Brabantse Ontwikkelings Maatschappij (BOM), Borski Fund, Prominent strategic angel fund.
Who are the founders of ShanX Medtech?
The founders of ShanX Medtech are: Dr Sophia E. Shanko.
What is ShanX Medtech and what is its primary focus?
ShanX Medtech is a medical technology company dedicated to developing innovative diagnostic solutions specifically aimed at combating antimicrobial resistance. The company focuses on creating rapid and portable diagnostic tools that provide clinicians with actionable data for effective patient treatment.
What specific product has ShanX Medtech developed for antibiotic testing?
The company has developed Smart-Dx, an advanced diagnostic platform designed for rapid antibiotic susceptibility testing. This device allows for the identification of the most effective antibiotic for a patient at the point of care, significantly reducing the turnaround time compared to traditional laboratory methods.
How does the technology from ShanX Medtech help healthcare providers?
By providing diagnostic results in hours rather than days, the technology enables healthcare providers to prescribe targeted antibiotic therapy immediately. This approach improves patient outcomes, reduces healthcare costs, and helps prevent the spread of drug-resistant infections by limiting the use of broad-spectrum antibiotics.
Where is ShanX Medtech located?
The company is based in India, operating out of the IIT Madras Research Park in Chennai. This location allows them to collaborate with leading researchers and access cutting-edge infrastructure for medical device development.
What makes the ShanX Medtech Smart-Dx platform unique in the medical field?
The platform is unique because of its ability to perform bedside antibiotic susceptibility testing using a miniaturized system. Its combination of speed, portability, and high sensitivity makes it a critical tool for intensive care units and clinics where timely treatment decisions are vital.